Opinion

Video

Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

Author(s):

Stephen J. Freedland, MD,Eleni Efstathiou, MD, PhD

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

  1. Dr. Efstathiou asks Dr. Freedland:Let's start by discussing the importance of early intervention in castration-sensitive prostate cancer (CSPC). What are the potential benefits of treating patients earlier in their disease course?
    1. How does early intervention impact long-term outcomes and quality of life?
    2. What are the risks of delaying systematic treatment?
  2. Dr. Freedland asks Dr. Efstathiou: Discuss the significance of biomarker and genetic testing, as well as imaging, in diagnosis of patients with prostate cancer.
    1. Briefly review guidelines for testing (NCCN Guidelines, Prostate Cancer)
    2. How do these results impact patient management? (eg, prognosis, risk stratification, treatment selection)
Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Prostate Cancer
December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
December 5th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer